CLRB: Cellectar Biosciences, Inc. Stock

by  •  • Comments Off on CLRB: Cellectar Biosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 14.59
Enterprise Value ($M) -6.80
Book Value ($M) 15.68
Book Value / Share 0.34
Price / Book 0.93
NCAV ($M) 14.45
NCAV / Share 0.31
Price / NCAV 1.01

Profitability (mra)
Return on Invested Capital (ROIC) -2.76
Return on Assets (ROA) -3.69
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 2.58
Current Ratio 2.58

Balance Sheet (mrq) ($M)
Current Assets 24.25
Assets 25.47
Liabilities 9.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -51.78
Net Income -44.58
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -47.58
Cash from Investing -0.10
Cash from Financing 61.41

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Nantahala Capital Management, LLC 5.73
02-13 13G/A Lytton Laurence W 8.80 -9.90
02-03 13G/A Rosalind Advisors, Inc. 9.90 103.53
01-27 13G/A Hirschman Orin 4.90 -24.04
11-14 13G/A ADAR1 Capital Management, LLC 8.51
2024-02-14 13G/A Lincoln Park Capital Fund, LLC 9.68 39.41

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-18 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-10-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2
2024-10-29 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)
2024-10-29 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1
2024-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-13 602,996 1,843,742 32.71
2025-03-12 102,185 422,570 24.18
2025-03-11 109,572 453,546 24.16
2025-03-10 343,584 1,208,646 28.43

(click for more detail)

Similar Companies
CKPT – Checkpoint Therapeutics, Inc. CLDX – Celldex Therapeutics, Inc.
CLNN – Clene Inc. CMPX – Compass Therapeutics, Inc.
CNSP – CNS Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io